123 related articles for article (PubMed ID: 8877681)
1. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data.
Yukawa E; Aoyama T
J Clin Pharmacol; 1996 Aug; 36(8):752-9. PubMed ID: 8877681
[TBL] [Abstract][Full Text] [Related]
2. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
3. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
J Clin Pharmacol; 1997 Dec; 37(12):1160-7. PubMed ID: 9506012
[TBL] [Abstract][Full Text] [Related]
4. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
Eur J Clin Pharmacol; 1998 Mar; 54(1):69-74. PubMed ID: 9591934
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
6. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.
Blanco-Serrano B; Otero MJ; Santos-Buelga D; García-Sánchez MJ; Serrano J; Domínguez-Gil A
Biopharm Drug Dispos; 1999 Jul; 20(5):233-40. PubMed ID: 10594867
[TBL] [Abstract][Full Text] [Related]
7. A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data.
Yukawa E
J Pharm Pharmacol; 1995 Dec; 47(12A):1048-52. PubMed ID: 8932693
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients.
Vučićević K; Jovanović M; Golubović B; Kovačević SV; Miljković B; Martinović Ž; Prostran M
Eur J Clin Pharmacol; 2015 Feb; 71(2):183-90. PubMed ID: 25380628
[TBL] [Abstract][Full Text] [Related]
9. Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview.
Yukawa E
Drug Metabol Drug Interact; 2000; 16(2):86-98. PubMed ID: 10962642
[TBL] [Abstract][Full Text] [Related]
10. A model for estimating individualized valproate clearance values in children.
Botha JH; Gray AL; Miller R
J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of carbamazepine in Singapore epileptic patients.
Chan E; Lee HS; Hue SS
Br J Clin Pharmacol; 2001 Jun; 51(6):567-76. PubMed ID: 11422016
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
14. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
15. Validation of a quick modeling program generating clearance estimates at steady state for routine therapeutic drug monitoring.
el Battah A; Beglia S; Alric R
Ther Drug Monit; 1995 Aug; 17(4):348-55. PubMed ID: 7482688
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis.
Bae EK; Lee J; Shin JW; Moon J; Lee KJ; Shin YW; Kim TJ; Shin D; Jang IJ; Lee SK
Seizure; 2016 Apr; 37():8-12. PubMed ID: 26908152
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing valproate pharmacokinetics in children and adults.
Jankovic SM; Milovanovic JR; Jankovic S
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):767-75. PubMed ID: 20979937
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of valproate in Mexican children with epilepsy.
Correa T; Rodríguez I; Romano S
Biopharm Drug Dispos; 2008 Dec; 29(9):511-20. PubMed ID: 19067436
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients.
Jiao Z; Zhong MK; Shi XJ; Hu M; Zhang JH
Ther Drug Monit; 2003 Jun; 25(3):279-86. PubMed ID: 12766553
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy.
Eriksson AS; Hoppu K; Nergårdh A; Boreus L
Epilepsia; 1996 Aug; 37(8):769-73. PubMed ID: 8764817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
